Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in the Treatment of Relapsed or Refractory Natural Killer / T-cell Lymphoma

NCT06573151 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06573151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06573151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in the Treatment of Relapsed or Refractory Natural Killer / T-cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2024
Completion date
July 1, 2027
Enrollment
28 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma